Glenmede Trust CO Na Intra Cellular Therapies, Inc. Transaction History
Glenmede Trust CO Na
- $20.6 Billion
- Q3 2024
A detailed history of Glenmede Trust CO Na transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Glenmede Trust CO Na holds 11,469 shares of ITCI stock, worth $982,205. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,469
Previous 12,758
10.1%
Holding current value
$982,205
Previous $873,000
4.01%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding ITCI
# of Institutions
377Shares Held
84.7MCall Options Held
319KPut Options Held
143K-
Vanguard Group Inc Valley Forge, PA9.63MShares$825 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.32MShares$541 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY5.29MShares$453 Million0.03% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.85MShares$330 Million1.4% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.05MShares$261 Million3.36% of portfolio
About Intra-Cellular Therapies, Inc.
- Ticker ITCI
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 94,401,696
- Market Cap $8.08B
- Description
- Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...